PATENT CLAIM ANALYSIS

Application Number: 15938952
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["424", "491000"]

Abstract:
The present invention provides methods and compositions for treating bladder cancer, including metastatic bladder cancer and non-muscle-invasive bladder cancer, by administering a composition comprising nanoparticles that comprise mTOR inhibitor and optionally an albumin.

Claim (Index 11):
The method of  claim 10 , wherein the second therapeutic agent is an immunotherapeutic agent.

Metadata:
- Claim Count in Document: 68.0
- Percentile: 90.0
- Lexical Diversity: 1.24138
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14772725', '13073861', '15192077', '12530188', '13782990']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7127823618192957
- 35 USC 102 Novelty (BERT): 0.6236809984764827
- Combined Prediction Score: 0.7038722254850144
- Mean Citation Score: 274.057166
- Max Citation Score: 455.20026
- Similarity Product: 358.78557141763326

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test